BELMONT, MA, Oryon Cell Therapies, a clinical-stage biotechnology company focused on developing autologous neuron replacement medicines for Parkinson's disease and other neurodegenerative disorders, announced it has emerged from stealth and has closed a new $21 million tranche of its Series A financing, bringing its total funding in equity and grants to $42 million.
more...